pI: 6.1068 |
Length (AA): 727 |
MW (Da): 79895 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
52 | 359 | 1p22 (A) | 259 | 544 | 17.00 | 0 | 1 | 0.59 | -0.07 |
199 | 266 | 1erj (A) | 448 | 518 | 38.00 | 0.00000014 | 1 | 0.64 | -1.13 |
95 | 373 | 2ovr (B) | 2417 | 2665 | 23.00 | 0.13 | 1 | 0.450569 | 0.56 |
199 | 266 | 1erj (A) | 448 | 518 | 38.00 | 0.000001 | 0.99 | 0.626335 | -1.01 |
202 | 265 | 2aq5 (A) | 93 | 164 | 31.00 | 0.052 | 0.79 | 0.401833 | -0.32 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | amastigotes. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127408)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G26460 | RNA splicing protein SMU2 |
Arabidopsis thaliana | AT2G34260 | protein WDR55 |
Babesia bovis | BBOV_III011140 | hypothetical protein |
Babesia bovis | BBOV_III004110 | hypothetical protein |
Brugia malayi | Bm1_57320 | Suppressor of mec and unc defects protein |
Brugia malayi | Bm1_46415 | hypothetical protein |
Caenorhabditis elegans | CELE_Y49F6B.4 | Protein SMU-2 |
Caenorhabditis elegans | CELE_Y44F5A.1 | Protein Y44F5A.1 |
Cryptosporidium parvum | cgd7_170 | hypothetical protein |
Dictyostelium discoideum | DDB_G0282573 | WD40 repeat-containing protein |
Dictyostelium discoideum | DDB_G0272070 | hypothetical protein |
Drosophila melanogaster | Dmel_CG18005 | CG18005 gene product from transcript CG18005-RA |
Drosophila melanogaster | Dmel_CG14722 | CG14722 gene product from transcript CG14722-RA |
Echinococcus granulosus | EgrG_001058800 | Protein Red |
Echinococcus granulosus | EgrG_000344200 | WD repeat containing protein 55 |
Entamoeba histolytica | EHI_006060 | WD domain containing protein |
Echinococcus multilocularis | EmuJ_000344200 | WD repeat containing protein 55 |
Echinococcus multilocularis | EmuJ_001058800 | Protein Red |
Homo sapiens | 54853 | WD repeat domain 55 |
Homo sapiens | ENSG00000113141 | IK cytokine, down-regulator of HLA II |
Leishmania braziliensis | LbrM.35.4960 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_364940.1 | hypothetical protein, conserved |
Leishmania infantum | LinJ.36.4940 | hypothetical protein, conserved |
Leishmania major | LmjF.36.4710 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.36.4710 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_01901 | hypothetical protein |
Loa Loa (eye worm) | LOAG_06696 | hypothetical protein |
Mus musculus | ENSMUSG00000042660 | WD repeat domain 55 |
Mus musculus | ENSMUSG00000024474 | IK cytokine |
Neospora caninum | NCLIV_065560 | hypothetical protein |
Neospora caninum | NCLIV_018010 | hypothetical protein |
Oryza sativa | 4344178 | Os07g0660700 |
Oryza sativa | 4351481 | Os12g0143400 |
Oryza sativa | 4349762 | Os11g0146700 |
Onchocerca volvulus | OVOC8855 | 3E324 homolog |
Plasmodium berghei | PBANKA_1241100 | WD repeat-containing protein, putative |
Plasmodium berghei | PBANKA_1405300 | RED-like protein, putative |
Plasmodium falciparum | PF3D7_1306800 | RED-like protein, putative |
Plasmodium falciparum | PF3D7_0526300 | WD repeat-containing protein, putative |
Plasmodium knowlesi | PKNH_1006500 | WD repeat-containing protein, putative |
Plasmodium knowlesi | PKNH_1407100 | RED-like protein, putative |
Plasmodium vivax | PVX_122175 | hypothetical protein, conserved |
Plasmodium vivax | PVX_079930 | WD domain, G-beta repeat domain containing protein |
Plasmodium yoelii | PY05613 | hypothetical protein |
Plasmodium yoelii | PY03863 | unnamed protein product |
Schistosoma japonicum | Sjp_0302480 | IPR001680,WD-40 repeat;IPR011046,WD40-like,domain-containing |
Schistosoma japonicum | Sjp_0080930 | Protein Red, putative |
Schistosoma mansoni | Smp_164290.1 | hypothetical protein |
Schistosoma mansoni | Smp_164290.2 | hypothetical protein |
Schistosoma mansoni | Smp_004480 | red protein (ik factor) (cytokine ik) |
Schmidtea mediterranea | mk4.000935.00 | |
Schmidtea mediterranea | mk4.038544.01 | Red protein |
Trypanosoma brucei gambiense | Tbg972.10.12300 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.10.10070 | hypothetical protein, conserved |
Trypanosoma congolense | TcIL3000_10_8320 | WD domain, G-beta repeat, putative |
Trypanosoma cruzi | TcCLB.508307.130 | hypothetical protein, conserved |
Toxoplasma gondii | TGME49_243240 | WD domain, G-beta repeat-containing protein |
Toxoplasma gondii | TGME49_249360 | RED family protein |
Theileria parva | TP03_0035 | hypothetical protein |
Theileria parva | TP02_0734 | hypothetical protein |
Theileria parva | TP03_0034 | hypothetical protein |
Trichomonas vaginalis | TVAG_074040 | WD-repeat protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.10070 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.10070 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.10070 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.10.10070 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_Y49F6B.4 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_Y44F5A.1 | Caenorhabditis elegans | slow growth | wormbase |
PBANKA_1405300 | Plasmodium berghei | Essential | plasmo |
TGME49_243240 | Toxoplasma gondii | Probably essential | sidik |
TGME49_249360 | Toxoplasma gondii | Probably essential | sidik |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | IK cytokine, down-regulator of HLA II | Compounds | References |